Alternating multiagent chemotherapy for advanced ovarian cancer

Enrique Hernandez, Neil B. Rosenshein, Jose Villar, Michael B. Dillon, David S. Ettinger, Stanley E. Order

Research output: Contribution to journalArticlepeer-review


A chemotherapy regimen consisting of hexamethylmelamine (H) 150 mg/ m2 orally days 1–14, cyclophosphamide (C) 500 mg/m2 IV day 1 of a 28‐day cycle with Adriamycin (A) 40 mg/m2 IV day 1 alternating with cisdiamminechloroplatinum (C‐P) 50 mg/m2 IV day 1 every other cycle was administered to 29 patients with advanced epithelial ovarian cancer. Toxicity to this regimen included alopecia, nausea, and vomiting in all patients. Mild paresthesias occurred in four patients. Hematologic toxicity required only minimal dose modification. There was no cardiac, renal, or auditory toxicity. The clinical response rate of 55% and median survival of 14 months compare favorably with that of other reported series. This chemotherapy regimen seems to be well tolerated without jeopardizing the patients' response.

Original languageEnglish (US)
Pages (from-to)87-91
Number of pages5
JournalJournal of Surgical Oncology
Issue number2
StatePublished - Feb 1983


  • chemotherapy
  • ovarian cancer
  • toxicity

ASJC Scopus subject areas

  • Surgery
  • Oncology


Dive into the research topics of 'Alternating multiagent chemotherapy for advanced ovarian cancer'. Together they form a unique fingerprint.

Cite this